Status:
UNKNOWN
Sickle Cell Disease: Targeting Alloantibody Formation Reduction; Risk Factors, and Genetics
Lead Sponsor:
Sanquin Research & Blood Bank Divisions
Collaborating Sponsors:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Radboud University Medical Center
Conditions:
Alloimmunization
Sickle Cell Disease
Eligibility:
All Genders
Brief Summary
The focus of the study is the pathophysiological mechanism of allo-antibody formation after red blood cell transfusion in sickle cell disease patients.
Detailed Description
The main objectives of this study are to study the role of the innate and adaptive immune response in allo-antibody formation and furthermore to identify the genetic and time dependent clinical risk f...
Eligibility Criteria
Inclusion
- Sickle cell disease
- Receiving a red blood cell transfusion
Exclusion
- Previous positive screen for allo-antibodies
- \>25 red blood cell units in the past
Key Trial Info
Start Date :
September 20 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT03288012
Start Date
September 20 2017
End Date
December 31 2021
Last Update
July 19 2019
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Academic Medical Center Amsterdam
Amsterdam-Zuidoost, Netherlands
2
Radboudumc
Nijmegen, Netherlands
3
Erasmus MC
Rotterdam, Netherlands
4
HagaZiekenhuis
The Hague, Netherlands